Loading
Moonlight Bio makes CAR-T cell therapy for solid tumours, adding gene changes found naturally in human T cells to make the treated cells multiply and last longer. Its first product, ML261, targets DLL3 and is in an early trial for small cell lung cancer and related neuroendocrine cancers.
Moonlight Bio, at 1150 Eastlake Avenue East, Seattle, Washington, develops adoptive T cell therapies for solid tumours enhanced with naturally occurring T cell mutations. Its founders compiled a library of genetic events from T cell disease states and screened them for variants that increase T cell proliferation, persistence and function, work published in Nature in 2024 (Garcia, Daniels et al., Naturally occurring T cell mutations enhance engineered T cell therapies). The lead candidate ML261 is an autologous, potency-enhanced CAR-T against DLL3, tested in the SPECTRAL-1 phase 1 study in relapsed or refractory small cell lung cancer and selected neuroendocrine carcinomas, including extrapulmonary, gastroenteropancreatic and neuroendocrine prostate cancers. Partners announced on its news page include MaxCyte (platform licence, October 2025), Kincell Bio (manufacturing collaboration for the lead candidate, October 2025), Leveragen, Cytogen and ZenQMS. Its first registered cancer trial, NCT07488923, was posted on ClinicalTrials.gov in March 2026.
Shares DLL3, Neuroendocrine tumours, Small-cell lung cancer.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares DLL3, Neuroendocrine tumours, Small-cell lung cancer.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares DLL3, Small-cell lung cancer.
Shares DLL3, Small-cell lung cancer.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares DLL3, Neuroendocrine and small-cell prostate cancer, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/